Progress towards a hepatitis C virus vaccine

New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost,...

Descripción completa

Detalles Bibliográficos
Autores principales: Man John Law, Lok, Landi, Abdolamir, Magee, Wendy C, Lorne Tyrrell, D, Houghton, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924556/
https://www.ncbi.nlm.nih.gov/pubmed/26038445
http://dx.doi.org/10.1038/emi.2013.79
_version_ 1782303758724628480
author Man John Law, Lok
Landi, Abdolamir
Magee, Wendy C
Lorne Tyrrell, D
Houghton, Michael
author_facet Man John Law, Lok
Landi, Abdolamir
Magee, Wendy C
Lorne Tyrrell, D
Houghton, Michael
author_sort Man John Law, Lok
collection PubMed
description New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost, it is unlikely that these HCV drugs will substantially reduce the world's HCV carrier population of around 170 million in the near future or the estimated global incidence of millions of new HCV infections. For these reasons, there is an urgent need to develop a prophylactic HCV vaccine and also to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. After much early pessimism on the prospects for an effective prophylactic HCV vaccine, our recent knowledge of immune correlates of protection combined with the demonstrated immunogenicity and protective animal efficacies of various HCV vaccine candidates now allows for realistic optimism. This review summarizes the current rationale and status of clinical and experimental HCV vaccine candidates based on the elicitation of cross-neutralizing antibodies and broad cellular immune responses to this highly diverse virus.
format Online
Article
Text
id pubmed-3924556
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39245562014-02-14 Progress towards a hepatitis C virus vaccine Man John Law, Lok Landi, Abdolamir Magee, Wendy C Lorne Tyrrell, D Houghton, Michael Emerg Microbes Infect Review New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost, it is unlikely that these HCV drugs will substantially reduce the world's HCV carrier population of around 170 million in the near future or the estimated global incidence of millions of new HCV infections. For these reasons, there is an urgent need to develop a prophylactic HCV vaccine and also to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. After much early pessimism on the prospects for an effective prophylactic HCV vaccine, our recent knowledge of immune correlates of protection combined with the demonstrated immunogenicity and protective animal efficacies of various HCV vaccine candidates now allows for realistic optimism. This review summarizes the current rationale and status of clinical and experimental HCV vaccine candidates based on the elicitation of cross-neutralizing antibodies and broad cellular immune responses to this highly diverse virus. Nature Publishing Group 2013-11 2013-11-20 /pmc/articles/PMC3924556/ /pubmed/26038445 http://dx.doi.org/10.1038/emi.2013.79 Text en Copyright © 2013 Shanghai Shangyixun Cultural Communication Co., Ltd http://creativecommons.org/licenses/by/3.0/ This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0
spellingShingle Review
Man John Law, Lok
Landi, Abdolamir
Magee, Wendy C
Lorne Tyrrell, D
Houghton, Michael
Progress towards a hepatitis C virus vaccine
title Progress towards a hepatitis C virus vaccine
title_full Progress towards a hepatitis C virus vaccine
title_fullStr Progress towards a hepatitis C virus vaccine
title_full_unstemmed Progress towards a hepatitis C virus vaccine
title_short Progress towards a hepatitis C virus vaccine
title_sort progress towards a hepatitis c virus vaccine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924556/
https://www.ncbi.nlm.nih.gov/pubmed/26038445
http://dx.doi.org/10.1038/emi.2013.79
work_keys_str_mv AT manjohnlawlok progresstowardsahepatitiscvirusvaccine
AT landiabdolamir progresstowardsahepatitiscvirusvaccine
AT mageewendyc progresstowardsahepatitiscvirusvaccine
AT lornetyrrelld progresstowardsahepatitiscvirusvaccine
AT houghtonmichael progresstowardsahepatitiscvirusvaccine